Physician profile
Rizwan Badar
NPI 1073761243
$2,732.92
in general payments reported to CMS, 2019-2025
24 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $182 · 2021: $130 · 2022: $280 · 2023: $347 · 2024: $601 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Education: $56.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.76 |
| Education | $56.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $324.27 | 2019-2024 | Parsabiv, Tavneos, Aranesp |
| Astrazeneca Pharmaceuticals Lp | $315.11 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $299.91 | 2019-2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $195.15 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $185.30 | 2019-2025 | Jynarque, Voyxact |
| Baxter Healthcare | $176.11 | 2019-2024 | |
| Vifor Pharma, INC. | $174.41 | 2019-2025 | Veltassa |
| Ardelyx, INC. | $148.32 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $141.13 | 2024-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $126.97 | 2023 | Benlysta |
| Travere Therapeutics, INC. | $116.59 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $69.07 | 2024-2025 | |
| Horizon Therapeutics Plc | $64.42 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.29 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.74 | 2024-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $58.27 | 2024-2025 | Lupkynis |
| Scpharmaceuticals INC. | $44.35 | 2025 | |
| Opko Pharmaceuticals, LLC | $40.29 | 2019-2025 | Rayaldee |
| Mallinckrodt Enterprises LLC | $30.73 | 2019 | |
| Ani Pharmaceuticals, INC. | $30.35 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $27.82 | 2019 | |
| Genentech USA, INC. | $16.41 | 2019 | |
| Fresenius USA Marketing, INC. | $16.38 | 2022 | |
| Lilly USA, LLC | $13.53 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Badar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.